YTHDF1 and neoplasm: To elucidate the role of YTHDF1 in patients with GC, we analyzed YTHDF1 protein expression in a second cohort of in‐house tissues from patients with GC (n = 400) using immunohistochemistry.[22] In central tumor regions, 63.5% of patients showed high expression of YTHDF1 (moderate, n = 186; strong, n = 68), whereas 36.5% of patients showed low expression of YTHDF1 (negative, n = 13, weak, n = 133) (Figure8A; Table S2, Supporting Information).